Type 1 diabetes affects millions worldwide and often begins in childhood, with no cure or prevention. This research uses early-life blood samples and single-cell immune profiling to identify genetic changes in immune cells before disease onset. The findings reveal new biomarkers that could enable early detection, targeted therapies, and future disease prevention.

This research investigates HMGN proteins, which organize the genome and help cells access the correct genes. By mapping their activity and removing them with CRISPR, the study shows that HMGNs act as DNA “librarians.” Their dysfunction leads to gene misregulation linked to many diseases.

This research investigates the safety of targeted synthetic DMARDs during pregnancy in people with autoimmune joint diseases. Using 20 years of population-level health data, it identifies increased risk of low birth weight associated with prenatal exposure. The findings aim to inform clinical guidance and empower patients to make safer, evidence-based decisions about pregnancy.

This research uses linked provincial health data to measure the population burden of coeliac disease in Alberta. By identifying diagnosis rates, care gaps, and early-life risk factors, the work informs healthcare planning and policy. The findings highlight rising diagnoses in children and the long-term personal and economic impact of a lifelong, diet-based condition.

This research explores how parasitic tapeworms suppress the immune system and how their mechanisms could inspire new treatments for autoimmune diseases. As infections decline, autoimmune conditions rise. Studying rat tapeworm–derived extracellular vesicles, the lab investigates how these molecular signals reprogram inflammatory macrophages, potentially leading to novel therapies that safely regulate immune dysfunction.

This research develops a nanoparticle-based diagnostic test for thrombotic thrombocytopenic purpura (TTP), a rare and deadly blood disorder. By enabling fast, affordable detection of the ADAMTS13 enzyme, the system could allow earlier diagnosis, timely treatment, and improved survival while inspiring new approaches to rare disease diagnostics.

Type 1 diabetes destroys insulin-producing cells, leaving patients dependent on lifelong injections. Islet transplants could provide freedom, but most cells die quickly. This research uses drug-loaded microparticles that protect transplanted islets, boosting survival, insulin production, and diabetes reversal. The approach could cut costs, reduce donor needs, and transform treatment for multiple diseases.